Strand eyes US, Southeast Asia mkts for blood-based cancer screening test
Reliance-backed genomics company is pursuing US FDA approval for CancerSpot and aims to cut its price in India to below ₹10,000 over the next two to three years.
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.